Genta Inc., of Berkeley Heights, N.J., said it has accrued its first patient in a trial of tesetaxel as initial chemotherapy for advanced or recurrent breast cancer. The randomized Phase IIb trial will enroll approximately 220 patients at 15 sites in the U.S. and Western Europe.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter